F Kierszenbaum

5.0k total citations
170 papers, 4.2k citations indexed

About

F Kierszenbaum is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, F Kierszenbaum has authored 170 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Epidemiology, 91 papers in Public Health, Environmental and Occupational Health and 44 papers in Immunology. Recurrent topics in F Kierszenbaum's work include Trypanosoma species research and implications (140 papers), Research on Leishmaniasis Studies (90 papers) and Synthesis and Biological Evaluation (24 papers). F Kierszenbaum is often cited by papers focused on Trypanosoma species research and implications (140 papers), Research on Leishmaniasis Studies (90 papers) and Synthesis and Biological Evaluation (24 papers). F Kierszenbaum collaborates with scholars based in United States, Argentina and Czechia. F Kierszenbaum's co-authors include Julia J. Wirth, Fernando Villalta, Delia B. Budzko, Marcelo B. Sztein, Maria F. Lima, Lisa A. Beltz, H.A. Molina, Sarmila Majumder, Gerald Sonnenfeld and Walter B. Dandliker and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and The Journal of Immunology.

In The Last Decade

F Kierszenbaum

168 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F Kierszenbaum United States 37 2.8k 1.9k 1.1k 837 774 170 4.2k
Z. Brener Brazil 38 4.7k 1.7× 3.4k 1.7× 752 0.7× 963 1.2× 1.0k 1.4× 141 5.3k
Nisha Garg United States 46 3.6k 1.3× 2.5k 1.3× 720 0.7× 1.3k 1.6× 1.0k 1.3× 142 5.2k
Janis Lazdins Switzerland 24 978 0.4× 750 0.4× 611 0.6× 491 0.6× 415 0.5× 41 2.6k
Jacques Mauël Switzerland 38 1.2k 0.5× 1.5k 0.8× 2.2k 2.0× 1.3k 1.6× 468 0.6× 102 5.2k
Murray Wittner United States 44 2.7k 1.0× 1.5k 0.8× 455 0.4× 1.0k 1.2× 2.2k 2.8× 161 5.4k
Manuel Carlos López Spain 34 2.2k 0.8× 1.8k 0.9× 495 0.4× 1.1k 1.3× 490 0.6× 153 3.8k
George A. DosReis Brazil 37 1.9k 0.7× 1.7k 0.9× 1.5k 1.4× 801 1.0× 670 0.9× 81 3.7k
Fernando Villalta United States 35 2.0k 0.7× 1.4k 0.7× 637 0.6× 1.1k 1.3× 262 0.3× 106 3.4k
Thaïs Souto-Padrón Brazil 35 1.9k 0.7× 1.3k 0.7× 465 0.4× 1.4k 1.6× 438 0.6× 107 3.6k
José O. Previato Brazil 37 2.6k 0.9× 1.3k 0.6× 815 0.7× 1.5k 1.9× 412 0.5× 142 4.1k

Countries citing papers authored by F Kierszenbaum

Since Specialization
Citations

This map shows the geographic impact of F Kierszenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Kierszenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Kierszenbaum more than expected).

Fields of papers citing papers by F Kierszenbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Kierszenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Kierszenbaum. The network helps show where F Kierszenbaum may publish in the future.

Co-authorship network of co-authors of F Kierszenbaum

This figure shows the co-authorship network connecting the top 25 collaborators of F Kierszenbaum. A scholar is included among the top collaborators of F Kierszenbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Kierszenbaum. F Kierszenbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kierszenbaum, F. (2005). Where do we stand on the autoimmunity hypothesis of Chagas disease?. Trends in Parasitology. 21(11). 513–516. 75 indexed citations
2.
Kierszenbaum, F, Manuel Fresno, & Marcelo B. Sztein. (2002). The Trypanosoma cruzi membrane glycoprotein AGC10 inhibits human lymphocyte activation by a mechanism preceding translation of both, interleukin-2 and its high-affinity receptor subunits. Molecular and Biochemical Parasitology. 125(1-2). 91–101. 12 indexed citations
4.
Estévez, Antonio M., et al.. (1999). Knockout of the glutamate dehydrogenase gene in bloodstream Trypanosoma brucei in culture has no effect on editing of mitochondrial mRNAs. Molecular and Biochemical Parasitology. 100(1). 5–17. 29 indexed citations
5.
Kierszenbaum, F. (1996). Can a killer be arrested?. Nature Medicine. 2(10). 1071–1072. 3 indexed citations
7.
Kierszenbaum, F, et al.. (1995). Trypanosoma cruz/‐induced decrease in the level of interferon‐7 receptor expression by resting and activated human blood lymphocytes. Parasite Immunology. 17(4). 207–214. 16 indexed citations
8.
Kierszenbaum, F. (1995). What are T-cell subpopulations really doing in chagas disease?. Parasitology Today. 11(1). 6–7. 9 indexed citations
9.
Yakubu, Momoh Audu, Sarmila Majumder, & F Kierszenbaum. (1994). Changes in Trypanosoma cruzi infectivity by treatments that affect calcium ion levels. Molecular and Biochemical Parasitology. 66(1). 119–125. 60 indexed citations
10.
Majumder, Sarmila & F Kierszenbaum. (1993). N,N′-Thiophene-substituted polyamine analogs inhibit mammalian host cell invasion and intracellular multiplication of Trypahosoma cruzi. Molecular and Biochemical Parasitology. 60(2). 231–239. 6 indexed citations
11.
Sztein, Marcelo B. & F Kierszenbaum. (1993). Mechanisms of development of immunosuppression during Trypanosoma infections. Parasitology Today. 9(11). 424–428. 26 indexed citations
13.
Wirth, Julia J. & F Kierszenbaum. (1988). Recombinant tumor necrosis factor enhances macrophage destruction of Trypanosoma cruzi in the presence of bacterial endotoxin.. The Journal of Immunology. 141(1). 286–288. 54 indexed citations
14.
Beltz, Lisa A., Marcelo B. Sztein, & F Kierszenbaum. (1988). Novel mechanism for Trypanosoma cruzi -induced suppression of human lymphocytes. Inhibition of IL-2 receptor expression.. The Journal of Immunology. 141(1). 289–294. 55 indexed citations
15.
McCann, Peter P., Cyrus J. Bacchi, Alan J. Bitonti, F Kierszenbaum, & Albert Sjoerdsma. (1988). Inhibition of Ornithine or Arginine Decarboxylase as an Experimental Approach to African or American Trypanosomiasis. Advances in experimental medicine and biology. 250. 727–735. 1 indexed citations
16.
Molina, H.A. & F Kierszenbaum. (1987). A study of human myocardial tissue in chagas' disease: distribution and frequency of inflammatory cell types. International Journal for Parasitology. 17(7). 1297–1305. 27 indexed citations
17.
Wirth, Julia J. & F Kierszenbaum. (1986). Stimulatory effects of retinoic acid on macrophage interaction with blood forms of Trypanosoma cruzi: involvement of transglutaminase activity.. The Journal of Immunology. 137(10). 3326–3331. 5 indexed citations
18.
Kierszenbaum, F. (1985). Is there autoimmunity in Chagas disease?. Parasitology Today. 1(1). 4–6. 43 indexed citations
20.
Kierszenbaum, F, et al.. (1982). Growth of Isolated Amastigotes of Trypanosoma cruzi in Cell-Free Medium. Journal of Eukaryotic Microbiology. 29(4). 570–576. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026